SUSTAINED DELIVERY OF HEPARIN INTO ARTERIAL WALL

Information

  • Research Project
  • 2421905
  • ApplicationId
    2421905
  • Core Project Number
    R43HL057692
  • Full Project Number
    1R43HL057692-01A1
  • Serial Number
    57692
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1997 - 26 years ago
  • Project End Date
    8/31/1998 - 25 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1997 - 26 years ago
  • Budget End Date
    8/31/1998 - 25 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/25/1997 - 26 years ago
Organizations

SUSTAINED DELIVERY OF HEPARIN INTO ARTERIAL WALL

The long range goal of this research program is to test several devices, based on the well-established basic principle of electroporation which allows delivery of exogenous molecules, intracellularly or pericellularly, and achieve effective and sustained delivery of various antithrombotic/antiproliferative agents into arterial wall. Application of this technology may overcome problems associated with the existing modality of drug delivery- systemic or local. Major application of such delivery would be in the areas of restenosis and treatment of intravascular thrombus. The Phase I proposal will deal with the following specific aims (i) extend the preliminary results obtained with the double-balloon electroporation catheter to include both the norma balloon-injured artery and the atherosclerotic rabbit models, serially, up to one month, with morphometric measurements, e.g., intima to media ratio, (ii) quantitate amount of heparin uptake by the mouse monoclonal anti-FITC probe that would bind to the FITC-labeled heparin, (iii) determine blood coagulation parameters, particularly APTT, for the pulsed and non-pulsed arteries, (iv) fabricate a prototype perfusion chamber and carry out in vitro studies with excised arteries or aorta and optimize pulsed parameters for maximum uptake of the agent, (v) obtain electric field plots using a software package for a given configuration of the catheter. PROPOSED COMMERCIAL APPLICATIONS The technique will allow development of devices for sustained, effective and in vivo local delivery of heparin and similar drugs which may overcome problems associated with the current mode of delivery.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    GENETRONICS, INC.
  • Organization Department
  • Organization DUNS
    122735749
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921211318
  • Organization District
    UNITED STATES